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Dear Sir,
Procalcitonin (PCT), the precursor of
calcitonin, is a new diagnostic parameter for
infections. There is evidence for PCT being a
more specific parameter indicating systemic
bacterial and fungal infections than the non-
specific acute-phase markers C-reactive pro-
tein (CRP) or apoferritin. Experimental data
and clinical observations have shown that
the main stimuli for PCT release are bacte-
rial endotoxins and proinflammatory cyto-
kines as seen in septicemia and bacteremia
[1, 2]. Both uremia and bioincompatibility
of hemodialysis (HD) result in a chronic sys-
temic inflammatory syndrome. Even when
ultrapure dialysate is used, there is evidence
for endotoxins or endotoxin fragments (lipid
A, muramyl peptides, molecular weight
!1 kD) crossing both low- and high-flux
membranes, leading to the activation of
monocytes and subsequent release of several
proinflammatory cytokines, such as interleu-
kin 1 and tumor necrosis factor alpha [3, 4].
The aim of our investigation was to charac-
terize PCT serum levels in patients without
systemic infections undergoing chronic dial-
ysis therapy.
Thirty-six patients on chronic HD and
10 patients on continuous ambulatory peri-
toneal dialysis (CAPD) were selected for the
study on the basis of absence of any clinical
evidence for infections during the last
3 weeks prior to the study and being without
active immunologic or acute thromboem-
bolic disorders, malignancies, or major sur-
gical procedures (28 men and 18 women
with a mean age of 58 B 24 years). All
patients had been on dialysis therapy for at
least 3 months. Informed consent was ob-
tained from all patients. Causes of chronic
renal failure were chronic glomerulonephri-
tis (n = 14), diabetic nephropathy (n = 10),
interstitial nephritis (n = 7), hypertensive
nephropathy (n = 6), nephroangiosclerosis
(n = 1), and undetermined causes (n = 6).
HD therapy was performed using high-flux
membranes (polysulfone F60S, Fresenius,
Bad Homburg, Germany; polyarylethersul-
fone H4, Hospal, Lyon, France) and bicar-
bonate-based dialysate. In 16 patients ultra-
pure dialysate was used. The endotoxin
count was always below 50 U/ml. Blood
samples were taken from the vascular access
site prior to dialysis therapy (basal state) and
from the efferent line at 15 min (time 15)
and at the end of the HD session (time 240).
In the CAPD patients blood was drawn from
a peripheral vein at routine visits. The PCT
levels were assayed using the LUMLtest®, an
immunoluminometric assay. The reference
range is below 0.5 ng/ml, but in healthy sub-
jects the PCT levels are usually below 0.1 ng/
ml [5]. CRP, leukocytes, and ferritin were
sampled at the same time points in EDTA
and serum tubes (Sarstedt) and analyzed by
autoanalyzer.
PCT was above the detectable level of
0.1 ng/ml in all 36 chronic HD patients be-
fore and at the end of HD. The PCT levels
were above 0.5 ng/ml in 16 patients (44%) at
baseline versus 9 patients (25%) at the end of
HD. On average the PCT levels decreased
from 0.58 B 0.35 ng/ml at baseline to 0.44
B 0.32 ng/ml at the end of HD (fig. 1, p !
0.05). In 1 of the 10 CAPD patients, the PCT
serum level was 0.8 ng/ml, in the remaining
9 patients the PCT levels were between 0.1
and 0.3 (0.23 B 0.11) ng/ml. CRP was below
Fig. 1. Mean PCT and CRP levels in 36 patients on chronic HD
without systemic infections.
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the limit of detection (!0.1 mg/dl) at all time
points in 10 patients on HD. CRP levels
above the normal range (0.5 mg/dl) were
found in 14 patients (38%) at baseline and in
18 patients (50%) at time 240, with a rise
from 0.57 B 0.44 mg/dl (baseline) to 0.70 B
0.51 mg/dl (time 240). Leukocytes were
within normal limits (4–10.8 ! 106/Ìl) in 34
patients (94%) at all time points. There was
an average decrease in leukocyte count of
11.5% after 15 min with a slow stabilizing
increase towards the end of the HD session,
a finding which is in accordance with the
well-known phenomenon of transient leuko-
penia within 15 min after the start of HD.
Due to intravenous supplementation of iron
aiming at an individual hematocrit level of
33%, the ferritin levels were about twice the
normal range.
Our investigation showed that PCT lev-
els are raised above the normal range of
0.5 ng/ml in almost every second chronic
HD patient. According to our results, raised
PCT levels confirm the presence of a chronic
systemic inflammatory state in HD patients.
This is not seen in patients on CAPD. 44%
of all HD patients without clinical or sys-
temic signs of infection had raised PCT
serum levels in the range of 0.6–1.5 ng/ml,
indicating that PCT levels !1.5 ng/ml do not
allow to differentiate between the inflamma-
tory state in chronic HD patients and incipi-
ent systemic bacterial infection. We, there-
fore, suggest a cutoff level for PCT !1.5 ng/
ml rather than !0.5 ng/ml as normal range
in patients undergoing chronic HD. The sig-
nificant decrease in PCT levels (on average
21%) during HD sessions may be explained
in part by the use of high-flux membranes.
Owing to its molecular weight of 13 kD,
PCR is abel to pass the membrane. In con-
trast, CRP is not lost into the dialysate
because of its molecular weight of 105.5 kD.
Dandona et al. [6] have shown that an initial
release of PCT in serum can be detected ear-
liest 4–6 h after stimulation of endotoxin.
Therefore, it is unlikely to observe a measur-
able increase of PCT levels during the course
of HD. This is the first description of PCT
levels during HD in patients without evi-
dence of systemic infections. Further investi-
gations are needed to elucidate the role of
PCT in the diagnosis of infections in patients
undergoing chronic HD.
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